Developer docs
API playgroundTry for free, no card

Search company profiles

TikoMed

Full company profile

uuid0002lvb

Namestring
TikoMed
Legal namestring
TikoMed AB
Websiteurl
tikomed.com
Company typeenum
Private
Founded yearint
2002
Descriptiontext

TikoMed AB is a privately-held Swedish biotechnology company founded in 2002 by the Bruce family, headquartered in Viken, Sweden, with 11–50 employees. The company develops a single drug platform asset, ILB®, a patented low molecular weight modified dextran sulfate compound discovered serendipitously. ILB® has a pleiotropic mechanism of action that stimulates endogenous release of heparin-binding growth factors (HGF, BDNF) from glypican reservoirs, downregulates neuroinflammation, and prevents fibrosis via decorin upregulation — effects that have been characterized across preclinical models of ALS, traumatic brain injury, stroke, glaucoma, limb ischemia, and viral infections (Dengue, Zika, Yellow Fever, SARS-CoV-2).

TikoMed's near-term development focus is Amyotrophic Lateral Sclerosis, where ILB® has completed Phase IIa trials at Sahlgrenska University Hospital and Queen Elizabeth Hospital Birmingham, and is now in the IMPACT Phase IIb study (120 patients, head-to-head versus riluzole) at Oslo University Hospital. The company has been granted Orphan Drug Designation by both the European Commission (2020) and the FDA for ILB® in ALS, providing 10 years of EU market exclusivity contingent on approval. In February 2026 the company signed a letter of intent with Karolinska Institutet to initiate the ILBIAMI study, ILB®'s first clinical investigation in myocardial infarction, expanding the pipeline into cardiology.

The business model is development-stage pharmaceutical: TikoMed funds clinical trials through equity and operates as an investment/holding structure developing projects through daughter companies, with explicit intent to monetize via licensing deals or trade sale to larger biopharma. Pricing is not publicly disclosed. The company is governed by a recently reconstituted Board (Göran Groth as Chairman from June 2025) and a Scientific Advisory Board of leading ALS experts (Cudkowicz, Ingre, Shefner, Chiò), with Dr. Björn Pilström appointed CEO in September 2025.

Short descriptiontext

TikoMed AB is a privately-held Swedish biotechnology company developing ILB®, a patented modified dextran sulfate drug candidate in Phase II clinical development for ALS and expanding into myocardial infarction, with EU and FDA Orphan Drug Designation.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersViken, Sweden
HQ citystring
Viken
HQ countrystring
Sweden
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
neurodegenerative therapeutics, ALS drug development, biopharmaceutical licensing, clinical stage biotechnology, drug candidate platform
Industry4 codes
PRIMARYHLAIACAB
Immunology & Autoimmune Specialty Pharmaceuticals
SECONDARYHLAIACAJ
Transplant & Immunosuppression Specialty Pharmaceuticals
SECONDARYHLAAABAL
Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAAAAAH
Therapeutic Peptides & Protein/Peptide Biologics
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
NAICS code3 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Scientific Research and Development Services5417
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Biological Products, (No Disgnostic Substances)2836
Product category
Biopharmaceutical Therapeutics
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model1 record
1Pharmaceutical Licensing/Partnering
TypeLicensing Royalties
Description

TikoMed develops drug candidates through clinical stages then exits through partnering deals or trade sale to biopharmas capable of progressing candidates to market. TikoMed AB is an investment/holding company that develops projects through daughter companies.

tikomed.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Personnel, Technology or R&D, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 record
1ILB®
Description

A modified form of dextran sulfate - TikoMed's lead drug candidate that stimulates the body's own repair mechanisms. ILB® has demonstrated neuroprotective and regenerative effects in neurodegenerative conditions including ALS, and has shown antiviral properties against various viruses.

tikomed.com
Core offering1 text field

TikoMed develops ILB®, a proprietary modified low-molecular-weight dextran sulfate drug platform with a pleiotropic mechanism that stimulates endogenous tissue repair by releasing growth factors (HGF, BDNF), modulating inflammatory response, and preventing fibrosis. The company advances ILB® through Phase II clinical trials primarily for amyotrophic lateral sclerosis (ALS), with expansion into myocardial infarction and other acute and chronic neurodegenerative indications. TikoMed plans to commercialize via licensing or trade-sale partnerships with larger biopharmaceutical companies.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 6 values shown
  • ALS progression halted/reversed in all 13 study participants assessed using ALSFRS-R and Norris clinical rating scales in Phase II trial at Sahlgrenska
+5 more records
Product overview1 text field

TikoMed is a Swedish biotechnology company that has developed ILB® as its core drug platform technology. ILB® is a modified low molecular weight dextran sulfate compound discovered serendipitously, with a broad pleiotropic mechanism of action that stimulates the body's endogenous repair systems by releasing growth factors and modulating inflammatory responses. The company's initial development programs focus on Amyotrophic Lateral Sclerosis (ALS), Traumatic Brain Injury (TBI), islet cell transplantation, and the company is exploring additional therapeutic indications such as myocardial infarction and various fibrotic diseases. The platform technology addresses the underlying pathology of disease rather than just treating symptoms, with potential applications across both acute and chronic neurodegenerative conditions.

Product and service1 record
1ILB®
CategoryDrug candidate / pharmaceutical compound
Description

ILB® is a modified low-molecular-weight dextran sulfate drug candidate with a pleiotropic mechanism of action that stimulates the body's own repair mechanisms. It triggers release of growth factors (HGF, BDNF) bound to glypican in blood-vessel walls, downregulates inflammatory responses, prevents fibrosis via decorin upregulation, and mitigates oxidative stress, mitochondrial dysfunction, and glutamate excitotoxicity. It is administered subcutaneously for long-term treatment and is being developed primarily for amyotrophic lateral sclerosis (ALS), with additional indications in traumatic brain injury, glaucoma, stroke, myocardial infarction, and viral infections.

Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-02-25
Description

Letter of intent signed for ILBIAMI clinical study evaluating ILB® in limiting heart muscle damage following myocardial infarction. Karolinska Institutet will serve as study sponsor while TikoMed provides active product, placebo substance, and scientific support. Study expected to begin 2026 pending regulatory approval. First clinical investigation of ILB® in this therapeutic indication.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-07-22
Description

Collaboration on Phase II clinical trial of ILB® in ALS patients at Queen Elizabeth Hospital Birmingham. Published results in PLOS ONE demonstrated safety and tolerability of long-term weekly ILB® injections in 11 ALS patients. Trial sponsored by University of Birmingham with TikoMed providing support.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-06-27
Description

Official research collaboration agreement signed for ALS clinical studies. TikoMed completed two successful Phase 2a clinical studies in ALS with promising results. The IMPACT Phase IIb study with 120 patients commenced enrollment in 2026. Oslo University Hospital serves as study sponsor with TikoMed providing ILB® and placebo.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2018-11-02
Description

Phase II ALS clinical trial collaboration with Dr. Lennart Persson as principal investigator. 15 patients with ALS received ILB® for a four-week treatment period followed by a three-month follow-up period. Study established safety and tolerability profile.

5Scientific Advisory Board (Merit Cudkowicz, Caroline Ingre, Jeremy Shefner, Adriano Chiò)
Strategic tierCoreTypeOthers
Description

Formed in September 2023 with world-renowned ALS experts from Mass General/Harvard, Karolinska Institutet, Barrow Neurological Institute, and University of Torino. Board advises management on Phase 2 clinical development and provides scientific credibility and network access.

tikomed.com
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeEmerging player
Description

Emerging clinical-stage biotech developing precision ALS therapies targeting ALS genetics and motor neuron biology. Comparable as a younger, venture-backed ALS-focused developer whose progress signals competitive dynamics and partnership M&A appetite in the ALS space.

TypeRegional player
Description

Dutch clinical-stage ALS-focused biotech developing TW001 (edaravone) and other ALS programs. European regional peer with a similar small-company, indication-focused model and a useful comparator for European ALS partnering pathways.

TypeDirect peer
Description

Clinical-stage biopharma developing ibudilast (MN-166) in ALS and other neurological conditions with anti-neuroinflammatory mechanism. Comparable to TikoMed in target indication (ALS), small-mid cap profile, and pleiotropic anti-inflammatory drug positioning.

TypeDirect peer
Description

Clinical-stage biopharma developing reldesemtiv and tirasemtiv for ALS and other neuromuscular diseases. Directly comparable late-stage ALS drug developer with a similar specialty-pharma profile and a similar partnering/exit pathway.

TypeBroad incumbent
Description

Large neuroscience biopharma with approved ALS therapy Tofersen (SOD1-ALS) and a broad neurology pipeline. Most relevant direct comparability is the Biogen/Ionis ASO platform addressing genetic ALS, a head-to-head benchmark for any ALS disease-modifying program like TikoMed's ILB®.

TypeBroad incumbent
Description

Established antisense oligonucleotide platform company with multiple neurological programs including partnered ALS assets with Biogen. Comparable as a broader neuroscience platform with established ALS exposure, and a likely partner/acquirer profile for late-stage ALS assets like ILB®.

TypeDirect peer
Description

Late-stage clinical developer of CNM-Au8, a gold nanocatalyst in Phase II/III trials for ALS, MS and Parkinson's. Closest direct peer in mechanism-flavor (novel neuroprotective platform) and indication focus (ALS), making it a key reference for valuation and clinical read-throughs.

TypeDirect peer
Description

Developer of NurOwn (autologous MSC neurotrophic-factor secreting cell therapy) for ALS, with completed Phase III. Direct peer in ALS disease-modifying therapies and a useful read-through on ALS trial design, regulatory expectations, and partnership outcomes.

9AB Science
TypeDirect peer
Description

European specialty pharma developing masitinib for ALS and other inflammatory/neurodegenerative indications. Direct peer in specialty-pharma positioning, immunomodulatory mechanism, and EU-based ALS development.

TypeDirect peer
Description

Clinical-stage biotech developing Engensis (VM202) gene therapy for ALS and other neurological indications. Comparable in indication, late-stage clinical status, and an example of a neuro-regenerative therapeutic competing in the same ALS opportunity set.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles12 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

TikoMed

Biopharmaceutical Therapeuticstikomed.com

TikoMed AB is a privately-held Swedish biotechnology company developing ILB®, a patented modified dextran sulfate drug candidate in Phase II clinical development for ALS and expanding into myocardial infarction, with EU and FDA Orphan Drug Designation.

What TikoMed does

TikoMed AB is a privately-held Swedish biotechnology company founded in 2002 by the Bruce family, headquartered in Viken, Sweden, with 11–50 employees. The company develops a single drug platform asset, ILB®, a patented low molecular weight modified dextran sulfate compound discovered serendipitously. ILB® has a pleiotropic mechanism of action that stimulates endogenous release of heparin-binding growth factors (HGF, BDNF) from glypican reservoirs, downregulates neuroinflammation, and prevents fibrosis via decorin upregulation — effects that have been characterized across preclinical models of ALS, traumatic brain injury, stroke, glaucoma, limb ischemia, and viral infections (Dengue, Zika, Yellow Fever, SARS-CoV-2).

TikoMed's near-term development focus is Amyotrophic Lateral Sclerosis, where ILB® has completed Phase IIa trials at Sahlgrenska University Hospital and Queen Elizabeth Hospital Birmingham, and is now in the IMPACT Phase IIb study (120 patients, head-to-head versus riluzole) at Oslo University Hospital. The company has been granted Orphan Drug Designation by both the European Commission (2020) and the FDA for ILB® in ALS, providing 10 years of EU market exclusivity contingent on approval. In February 2026 the company signed a letter of intent with Karolinska Institutet to initiate the ILBIAMI study, ILB®'s first clinical investigation in myocardial infarction, expanding the pipeline into cardiology.

The business model is development-stage pharmaceutical: TikoMed funds clinical trials through equity and operates as an investment/holding structure developing projects through daughter companies, with explicit intent to monetize via licensing deals or trade sale to larger biopharma. Pricing is not publicly disclosed. The company is governed by a recently reconstituted Board (Göran Groth as Chairman from June 2025) and a Scientific Advisory Board of leading ALS experts (Cudkowicz, Ingre, Shefner, Chiò), with Dr. Björn Pilström appointed CEO in September 2025.

TikoMed firmographics

Firmographics
Name
TikoMed
Legal name
TikoMed AB
Website
https://tikomed.com
Company type
Private
Founded year
2002
Operating status
Operating
Headcount range
1–10 employees
Short description
TikoMed AB is a privately-held Swedish biotechnology company developing ILB®, a patented modified dextran sulfate drug candidate in Phase II clinical development for ALS and expanding into myocardial infarction, with EU and FDA Orphan Drug Designation.
Ownership category
akta.pro rank

TikoMed industry classification

Industry
Product category
Biopharmaceutical Therapeutics
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
SIC
Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAIACAB
Immunology & Autoimmune Specialty Pharmaceuticals
SECONDARYHLAIACAJ
Transplant & Immunosuppression Specialty Pharmaceuticals
SECONDARYHLAAABAL
Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAAAAAH
Therapeutic Peptides & Protein/Peptide Biologics
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)

Keywords

  • Neurodegenerative therapeutics
  • ALS drug development
  • Biopharmaceutical licensing
  • Clinical stage biotechnology
  • Drug candidate platform

Where TikoMed is headquartered

Location

Headquarters

HQ city
Viken
HQ country
Sweden
HQ region
Europe

Offices2 records

Markets served

TikoMed business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales

Revenue model

  1. Pharmaceutical Licensing/Partnering: TikoMed develops drug candidates through clinical stages then exits through partnering deals or trade sale to biopharmas capable of progressing candidates to market. TikoMed AB is an investment/holding company that develops projects through daughter companies.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels5 records

TikoMed product offering

Product offering

Core offering

TikoMed develops ILB®, a proprietary modified low-molecular-weight dextran sulfate drug platform with a pleiotropic mechanism that stimulates endogenous tissue repair by releasing growth factors (HGF, BDNF), modulating inflammatory response, and preventing fibrosis. The company advances ILB® through Phase II clinical trials primarily for amyotrophic lateral sclerosis (ALS), with expansion into myocardial infarction and other acute and chronic neurodegenerative indications. TikoMed plans to commercialize via licensing or trade-sale partnerships with larger biopharmaceutical companies.

Product overview

TikoMed is a Swedish biotechnology company that has developed ILB® as its core drug platform technology. ILB® is a modified low molecular weight dextran sulfate compound discovered serendipitously, with a broad pleiotropic mechanism of action that stimulates the body's endogenous repair systems by releasing growth factors and modulating inflammatory responses. The company's initial development programs focus on Amyotrophic Lateral Sclerosis (ALS), Traumatic Brain Injury (TBI), islet cell transplantation, and the company is exploring additional therapeutic indications such as myocardial infarction and various fibrotic diseases. The platform technology addresses the underlying pathology of disease rather than just treating symptoms, with potential applications across both acute and chronic neurodegenerative conditions.

Differentiator

Problem solved

Functional benefit

Brands

  • ILB®: A modified form of dextran sulfate - TikoMed's lead drug candidate that stimulates the body's own repair mechanisms. ILB® has demonstrated neuroprotective and regenerative effects in neurodegenerative conditions including ALS, and has shown antiviral properties against various viruses.

Products and services

  • ILB® ILB® is a modified low-molecular-weight dextran sulfate drug candidate with a pleiotropic mechanism of action that stimulates the body's own repair mechanisms. It triggers release of growth factors (HGF, BDNF) bound to glypican in blood-vessel walls, downregulates inflammatory responses, prevents fibrosis via decorin upregulation, and mitigates oxidative stress, mitochondrial dysfunction, and glutamate excitotoxicity. It is administered subcutaneously for long-term treatment and is being developed primarily for amyotrophic lateral sclerosis (ALS), with additional indications in traumatic brain injury, glaucoma, stroke, myocardial infarction, and viral infections.

Quantifiable outcome

  • ALS progression halted/reversed in all 13 study participants assessed using ALSFRS-R and Norris clinical rating scales in Phase II trial at Sahlgrenska
  • +5 more outcomes

Companies that use TikoMed

Customer profile

Named customers3 records

Segments4 records

Ideal customer profiles2 records

TikoMed technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

TikoMed partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered core.

  • Karolinska Institutet (Department of Medicine Solna)coreStrategic or Co-development Partner · 25 February 2026Letter of intent signed for ILBIAMI clinical study evaluating ILB® in limiting heart muscle damage following myocardial infarction. Karolinska Institutet will serve as study sponsor while TikoMed provides active product, placebo substance, and scientific support. Study expected to begin 2026 pending regulatory approval. First clinical investigation of ILB® in this therapeutic indication.
  • University of Birmingham (D3B Team - Queen Elizabeth Hospital)coreStrategic or Co-development Partner · 22 July 2024Collaboration on Phase II clinical trial of ILB® in ALS patients at Queen Elizabeth Hospital Birmingham. Published results in PLOS ONE demonstrated safety and tolerability of long-term weekly ILB® injections in 11 ALS patients. Trial sponsored by University of Birmingham with TikoMed providing support.
  • Oslo University Hospital (Division of Clinical Neuroscience)coreStrategic or Co-development Partner · 27 June 2024Official research collaboration agreement signed for ALS clinical studies. TikoMed completed two successful Phase 2a clinical studies in ALS with promising results. The IMPACT Phase IIb study with 120 patients commenced enrollment in 2026. Oslo University Hospital serves as study sponsor with TikoMed providing ILB® and placebo.
  • Sahlgrenska University HospitalcoreStrategic or Co-development Partner · 2 November 2018Phase II ALS clinical trial collaboration with Dr. Lennart Persson as principal investigator. 15 patients with ALS received ILB® for a four-week treatment period followed by a three-month follow-up period. Study established safety and tolerability profile.
  • Scientific Advisory Board (Merit Cudkowicz, Caroline Ingre, Jeremy Shefner, Adriano Chiò)coreOthersFormed in September 2023 with world-renowned ALS experts from Mass General/Harvard, Karolinska Institutet, Barrow Neurological Institute, and University of Torino. Board advises management on Phase 2 clinical development and provides scientific credibility and network access.

Scale indicators3 records

Recent moves6 records

Expansion highlights5 records

TikoMed competitors and assessment

Company assessment

Emerging players

  • QurAlis Corporation: Emerging clinical-stage biotech developing precision ALS therapies targeting ALS genetics and motor neuron biology. Comparable as a younger, venture-backed ALS-focused developer whose progress signals competitive dynamics and partnership M&A appetite in the ALS space.

Regional players

  • Treeway B.V. Dutch clinical-stage ALS-focused biotech developing TW001 (edaravone) and other ALS programs. European regional peer with a similar small-company, indication-focused model and a useful comparator for European ALS partnering pathways.

Direct peers

  • MediciNova: Clinical-stage biopharma developing ibudilast (MN-166) in ALS and other neurological conditions with anti-neuroinflammatory mechanism. Comparable to TikoMed in target indication (ALS), small-mid cap profile, and pleiotropic anti-inflammatory drug positioning.
  • Cytokinetics: Clinical-stage biopharma developing reldesemtiv and tirasemtiv for ALS and other neuromuscular diseases. Directly comparable late-stage ALS drug developer with a similar specialty-pharma profile and a similar partnering/exit pathway.
  • Clene Nanomedicine: Late-stage clinical developer of CNM-Au8, a gold nanocatalyst in Phase II/III trials for ALS, MS and Parkinson's. Closest direct peer in mechanism-flavor (novel neuroprotective platform) and indication focus (ALS), making it a key reference for valuation and clinical read-throughs.
  • BrainStorm Cell Therapeutics: Developer of NurOwn (autologous MSC neurotrophic-factor secreting cell therapy) for ALS, with completed Phase III. Direct peer in ALS disease-modifying therapies and a useful read-through on ALS trial design, regulatory expectations, and partnership outcomes.
  • AB Science: European specialty pharma developing masitinib for ALS and other inflammatory/neurodegenerative indications. Direct peer in specialty-pharma positioning, immunomodulatory mechanism, and EU-based ALS development.
  • Helixmith: Clinical-stage biotech developing Engensis (VM202) gene therapy for ALS and other neurological indications. Comparable in indication, late-stage clinical status, and an example of a neuro-regenerative therapeutic competing in the same ALS opportunity set.

Broad incumbents

  • Biogen: Large neuroscience biopharma with approved ALS therapy Tofersen (SOD1-ALS) and a broad neurology pipeline. Most relevant direct comparability is the Biogen/Ionis ASO platform addressing genetic ALS, a head-to-head benchmark for any ALS disease-modifying program like TikoMed's ILB®.
  • Ionis Pharmaceuticals: Established antisense oligonucleotide platform company with multiple neurological programs including partnered ALS assets with Biogen. Comparable as a broader neuroscience platform with established ALS exposure, and a likely partner/acquirer profile for late-stage ALS assets like ILB®.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

TikoMed social profiles

Digital presence

TikoMed compliance and trust

Trust signal

Compliance1 record

TikoMed financial estimates

Financial estimate

Revenue estimate

Valuation estimate

TikoMed leadership team

Management profile

Number of profiles

Profiles12 records

TikoMed funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

TikoMed M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about TikoMed

What does TikoMed do?

TikoMed develops ILB®, a proprietary modified low-molecular-weight dextran sulfate drug platform with a pleiotropic mechanism that stimulates endogenous tissue repair by releasing growth factors (HGF, BDNF), modulating inflammatory response, and preventing fibrosis. The company advances ILB® through Phase II clinical trials primarily for amyotrophic lateral sclerosis (ALS), with expansion into myocardial infarction and other acute and chronic neurodegenerative indications. TikoMed plans to commercialize via licensing or trade-sale partnerships with larger biopharmaceutical companies.

Is TikoMed a public or private company?

TikoMed is a private company. It is classified as family owned and is currently operating.

When was TikoMed founded?

TikoMed was founded in 2002. It employs 1 to 10 people.

Where is TikoMed based?

TikoMed is headquartered in Viken, Sweden, in the Europe region.

How does TikoMed make money?

One revenue line is on record: pharmaceutical Licensing/Partnering.

Who are TikoMed's main competitors?

QurAlis Corporation is listed as an emerging player. Treeway B.V. is listed as a regional player. Direct peers are MediciNova, Cytokinetics, Clene Nanomedicine, BrainStorm Cell Therapeutics, AB Science and Helixmith. Broad incumbents are Biogen and Ionis Pharmaceuticals.

Does TikoMed have an API?

No public API is recorded for TikoMed.

What industry is TikoMed in?

TikoMed's product category is Biopharmaceutical Therapeutics. Its primary akta.pro industry code is HLAIACAB, Immunology & Autoimmune Specialty Pharmaceuticals, with a secondary code of HLAIACAJ, Transplant & Immunosuppression Specialty Pharmaceuticals. Its NAICS code is 325414 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
news.cision.comOslo University Hospital begins ALS study with TikoMed’s drug candidate ILB[®]Oslo University Hospital has begun enrolling patients in the IMPACT study, a clinical trial investigating the efficacy and safety of TikoMed's drug candidate ILB® compared to riluzole for the treatment of ALS. The study will include 120 patients from Norway in a randomized 6-month phase followed by a 6-month open-label phase where all patients receive both medications. TikoMed, a Swedish biotechnology company, is providing ILB® and placebo for the study, with CEO Björn Pilström expressing enthusiasm for the trial.news.cision.comTikoMed signs letter of intent with Karolinska Institutet on myocardial infarction studyTikoMed AB and the Department of Medicine Solna at Karolinska Institutet have signed a letter of intent to collaborate on a clinical study called ILBIAMI, evaluating the effect of ILB® in limiting heart muscle damage following myocardial infarction. Karolinska Institutet will serve as the study sponsor while TikoMed provides the active product, placebo substance, and scientific support. The study, expected to begin in 2026 pending regulatory approval, represents the first clinical investigation of ILB® in this therapeutic indication.PR NewswireOslo University Hospital to conduct randomized phase 2 trial of ILB® in ALS; Tikomed to supply ILB for both study phasesOslo University Hospital announced the startup of a multicenter randomized phase 2 trial of ILB® for ALS, beginning in early 2026 and enrolling 116 patients over a 12-month period. The study will compare ILB® against Riluzole (the current standard of care) in a 6-month double-blind phase, followed by a 6-month open-label extension where patients receive both treatments. Tikomed, a Swedish pharmaceutical company, will supply ILB® and corresponding placebo for both study phases, with results expected by the end of 2028.PR NewswireOslo University Hospital to conduct randomized phase 2 trial of ILB® in ALS; Tikomed to supply ILB for both study phasesOslo University Hospital is launching a multicenter randomized phase 2 trial of Tikomed's ILB® drug candidate for ALS treatment, beginning in early 2026 with 116 patients over a 12-month period. The study will compare ILB® against Riluzole (the current standard of care) in a double-blind phase followed by an open-label extension, with Tikomed supplying the drug and corresponding placebo for both phases. Results from the trial, which has received all required regulatory approvals and is funded by public research grants, are expected by the end of 2028.PR NewswireTikoMed's ILB® mobilizes and modulates key growth factors that trigger a cascade of neuroprotective mechanisms able to target all neuroinflammation-driven diseases including ALSTikoMed announced the publication of peer-reviewed research in Frontiers in Pharmacology supporting the neuroprotective mechanism of its ILB® drug platform. The studies indicate that ILB® mobilizes and modulates heparin-binding growth factors to address neuroinflammation-driven diseases, including ALS and traumatic brain injury. Consequently, TikoMed has initiated development programs for these conditions and is considering broader applications.PR NewswireTikoMed's ILB® activates the body's natural repair signals to restore glutamate homeostasis, amino acid metabolism and neurocognitive functions in a rat model of severe traumatic brain injuryA new study on TikoMed's drug candidate ILB® was published in the International Journal of Molecular Sciences, demonstrating in a rat model of severe traumatic brain injury (sTBI) that a single dose administered 30 minutes after injury prevents glutamate excitotoxicity and normalizes amino acid levels involved in brain metabolic functions. The research shows ILB® activates growth factors that protect nerve cells by improving mitochondrial functions and energy metabolism while reducing oxidative stress, resulting in significantly improved neurocognitive functions. TikoMed's CEO stated confidence in the ongoing clinical development program and upcoming additional study results validating ILB®'s mechanism of action for acute and chronic degenerative neurological diseases.BioSpaceTikoMed Touts “Disease-modifying” Potential for ALS AssetTikoMed announced that its lead ALS drug candidate ILB halted or reversed disease progression in a Phase II trial, published in PLOS ONE. The study found no serious adverse events and elevated plasma Hepatocyte Growth Factor, supporting ILB's potential as a disease-modifying treatment. The company is also investigating ILB for glaucoma and stroke.PR NewswireTikoMed AB reports positive phase II clinical data for the treatment of Amyothropic Lateral Sclerosis in data published by PLOS ONETikoMed AB announced positive Phase II clinical trial data for its drug candidate ILB® in the treatment of amyotrophic lateral sclerosis (ALS), with results published in PLOS ONE. The open-label study, conducted at Sahlgrenska University Hospital in Gothenburg, Sweden, with 13 patients over five weeks, showed that ILB® halted or reversed disease progression in all assessed participants, with a favorable safety and tolerability profile and no patient withdrawals. The CEO highlighted the significance of these findings, noting that numerous prior trials have failed to identify any agent capable of reversing or halting ALS symptoms.PR NewswireTIKOMED'S ILB® restores brain energy metabolism following severe traumatic brain injury in the rat demonstrated in data published by the journal AntioxidantsA study on TIKOMED's drug candidate ILB® was published in the journal Antioxidants, demonstrating that a single post-injury injection of ILB® improved brain metabolism and reduced tissue damage in a rodent model of severe traumatic brain injury. The research showed dose-dependent improvements in brain energy metabolism, inhibition of oxidative stress, and preservation of antioxidants following sTBI. The findings provide preclinical evidence supporting future clinical trials for TBI treatment, a condition described as a leading cause of death for those under 45 in Western countries.NewswireTIKOMED Secures 5M Euro Funding for the Clinical Development of ILB™ and IBSOLVMIR®TIKOMED completed a 5 million Euro financing round from current investors to support clinical development of ILB and IBSOLVMIR. The company is running phase II trials in ALS and islet cell transplantation, with data planned for 2020.